Form 4: Centessa GC Exercises Options, Sells Shares

Centessa Pharmaceuticals General Counsel Iqbal J Hussain exercised stock options and subsequently sold a portion of his shares under a pre-arranged trading plan.

Summary

• Iqbal J Hussain, General Counsel of Centessa Pharmaceuticals plc, reported changes in beneficial ownership of Ordinary Shares.
• On October 15, 2025, Hussain acquired 6,000 Ordinary Shares by exercising stock options at a price of $5.84 per share.
• Immediately following the acquisition, Hussain directly owned 111,386 Ordinary Shares.
• On the same date, Hussain disposed of 6,000 Ordinary Shares through a sale at a weighted average price of $22.4065 per share.
• The sales were executed pursuant to a Rule 10b5-1 trading plan adopted on September 14, 2024.
• After these transactions, Hussain directly owns 105,386 Ordinary Shares and indirectly owns 5,500 Ordinary Shares through his spouse.
• The exercised share option had an exercise price of $5.84 and an expiration date of February 19, 2031.
• The options vested 25% on February 19, 2022, with the remaining 75% vesting in 36 monthly installments thereafter.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While insider selling can sometimes be viewed negatively, the transaction was pre-planned under a Rule 10b5-1 plan, which mitigates concerns about opportunistic selling based on undisclosed information. It represents a routine financial management activity for the insider.

Positives

• The insider's exercise of options at a significantly lower price ($5.84) and subsequent sale at a higher price ($22.4065) indicates a profitable transaction for the individual.
• The transaction was conducted under a Rule 10b5-1 trading plan, indicating pre-planned financial management rather than a reaction to immediate company news.

Negatives

• Insider selling, even when pre-planned, can sometimes be perceived by investors as a lack of strong conviction in the company's near-term stock price appreciation, though it is often for personal financial diversification.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This filing is a routine insider transaction report and does not provide information related to broader industry trends or competitive landscape.

Stakeholder Impact

• Shareholders: May observe the General Counsel's decision to monetize some stock, which is a common personal financial planning activity. The pre-planned nature of the sale under a 10b5-1 plan generally reduces any negative implications.

Key Dates

Keywords

Centessa Pharmaceuticals, CNTA, Form 4, Insider Trading, Stock Options, Share Sale, Iqbal J Hussain, Rule 10b5-1